Science Pharmaceutical-B two high two years report

20244292024429 46621 183171712-1716 33191918 02171 P.O. Box 31119Grand PavilionHibiscus Way802 West Bay RoadGrand Cayman KY1-1205Cayman Islands 97927 www.carsgen.com Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman KY1-1102Cayman Islands 717710 3A10 46 2024 CAR-T 202312FDA(CGMP)483賽愷澤®CT053CT041CT071FDA202411 賽愷澤®2024223(NMPA)(R/R MM)3CAR-T15420248102 CLDN18.2CAR-TGC/GEJIIIINMPACDE(BTD)2025NMPA(NDA)CAR-T CAR-T2024(ASH)THANK-uCAR®BCMACAR-TCT0590I52(sCR)(DoR)20THANK-uPlus™THANK-uCAR®NKTHANK-u Plus™CAR-TCAR-T CAR-TCAR-TCAR-T 2024 1. 2024123139.4賽愷澤®BCMACAR-T20241231賽愷澤®75CAR-T 2. 2024123114.7 3. 202412317982023123174850202312313122920241231260(i)2023123166219620241231466(ii)202412311520231231 20241231(1)7892023123173356(i)(ii)(iii)(iv) 4. 202412311,479202312311,85037120251,0802028 (1) 賽愷澤®CT053 賽愷澤®B(BCMA)CAR-T202431NMPA賽愷澤®2024223(R/RMM)3000963.SZ賽愷澤®賽愷澤®20241231賽愷澤®23154賽愷澤®II29(EHA)66ASH賽愷澤® CT041 Claudin18.2(CLDN18.2)CAR-TGC/GEJII(NCT04581473)(IRC)(PFS)PFSIINMPACDEBTD(CT041-CG4006, NCT03874897)20246Nature Medicine202462024(ASCO)(PC)CT041-CG4006CT041-ST-01Journal of Clinical Oncology Claudin18.2I(CT041-ST-05, NCT05911217)(CT041-CG4010NCT06857786)20241031FDA CAR-T THANK-uCAR®CAR-TTHANK-uPlus™THANK-uCAR®CAR-TNKG2A THANK-uCAR®BCMACAR-TCT0590IIT20241266ASHCT0590BCMANKG2ACAR-TA First-in-Human Study of CT0590, a TripleKnock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/RefractoryMultiple Myeloma CAR-TBCMAR/RMM(R/RPCL)CT059X(THANK-uPlus™)CD19/CD20BKJ-C2219(THANK-uPlus™)CD38AMLKJ-C2320THANK-uCAR®KJ-C2114(THANK-uPlus™)NKG2DLKJ-C2526 (THANK-u Plus™) I. CAR-TCAR-TCAR-T II. CAR-TCAR-T 2024賽愷澤®CT0533賽愷澤®賽愷澤® C T 0 7 1G P R C 5 DCARcelerate®CT071(CT041)GC/GEJII(CT041-ST-01,NCT04581473)IRCPFSCAR-TIGC/GEJI C A R - TTHANK-uCAR®CAR-TTHANK-uPlus™CAR-TBCMAR/RMMR/RPCLCT0590THANK-uCAR®BCMAR/RMMR/RPCLCT059X(THANK-uPlus™)CD19/CD20BKJ-C2219(THANK-uPlus™)CD38AMLKJ-C2320THANK-uCAR®KJ-C2114(THANK-uPlus™)NKG2DLAMLKJ-C2526(THANK-u Plus™) 1.2.II3.SZ000963HKInno.N Corporation1959404.CT0590 賽愷澤®CT053BCMA CAR-T 賽愷澤®R/R MMBCMA CAR-TBCMA(scFv)CARCAR-TT 202431NMPA賽愷澤®2024223R/RMM320231賽愷澤®200751,025賽愷澤®賽愷澤®20241231賽愷澤®23154 賽愷澤® 賽愷澤®LUMMICAR STUDY 120241266ASH2B C M AC A R - TSubgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully HumanBCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory MultipleMyeloma LUMMICAR-1202461529EHABCMACAR-T2Phase 2study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed/refractory multiple myeloma102賽愷澤®(ORR)92.2% (94/102)(VGPR)91.2%(93/102)(CR)(sCR)71.6% (73/102) 20231265ASHLummicar1I3Three-Year Follow-Up onEfficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in ChinesePatientswith Relapsed or Refractory Multiple MyelomaI/II(LUMMICAR-1, NCT03975907)I3 20241031FDALUMMICAR-2 18A.08(3) CT041Claudin18.2 CAR-T Claudin18.2CAR-TClaudin18.2GC/GEJPCClaudin18.2GC/GEJPCCAR-TClaudin18.2CAR-TCAR-T II(CT041-ST-01,NCT04581473)IRCPFS2025NMPANDA PCI(CT041-ST-05NCT05911217)GC/GEJCT041-CG4010NCT06857786 CT041-CG4006202463NatureMedicineClaudin18.2CAR-TIClaudin18.2-specific CART cells in gastrointestinal cancers: Phase 1 trial final results202462024ASCOGC/GEJn=5951(DCR)54.9% (28/51)96.1% (49/51) 20245CT041Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A PooledAnalysis of Two Early-Phase TrialsJournal of Clinical OncologyI/IbCT041-CG4006CT041-ST-01 2 0 2 42C l a u d i n 1 8 . 2 - C A RTM e t a s t a t i cgastriccancer target lesion complete response with Claudin18.2-CAR T cellsJournal forImmunoTherapyof Cancer28 20239NCT04581473NCT03874897Journal of Hematology & OncologyCT041 CAR-TClaudin18.2CT041 CAR T cell therapy for Claudin18.2-positive metastaticpancreatic cancer Ib/II(CT041-ST-01NCT04581473)Ib2022ASCOCLDN18.2 CAR T(CT041)lb/llSafety, Tolerability and Preliminary Efficacy Results inPatients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma from a Phase lb/ll Study ofCLDN18.2 CAR T-cell therapy (CT041) 1b/2CT041-ST-02NCT04404595GC/GEJ2FDA1b2024ASCO GICLDN18.2TELIMYN18.2 1bCLDN18.2 Chimeric Antigen Receptor TCell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma: Results of ELIMYN18.2Phase 1b Clinical Trial G C / G E J2 0 2 09F D AClaudin18.2GC/GEJ20221FDARMATII20253NMPACDEBTDClaudin18.2GC/GEJ MRNAModerna,Inc.Claudin18.2mRNA2023 18A.08(3) CT011GPC3 CAR-T CT011CAR-T(HCC)GPC3CAR-THCC 20237CAR-GPC3 TCombined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concepttreatment strategyCancer CommunicationGPC3 CAR-THCC7 20241CT011NMPAINDGPC3IIIa 18A.08(3)CT011 CT071 – GPRC5D CAR-T CT071CARcelerate®GPRC5DCAR-TR/RMMR/R pPCL(scFV) CARcelerate®CT07130CAR-T CT071IIT(NCT05838131)20241266ASHGPRC5DCAR-TCT071GPRC5D-Targeted CART-Cell Therapy CT071